bestcryptogamingplatform| Tianyan Pharmaceutical's intraday movements rose rapidly by 5.02% to US$2.72

Beijing time at 23:05 on May 22, 2024bestcryptogamingplatform, Tianyan Pharmaceutical (ADAGbestcryptogamingplatform.us) Stocks changed, and the stock price quickly rose by 5.02%. As of press time, the stock was trading at US$2.72/share, with a trading volume of 3031 shares, a turnover rate of 0.01%, and an amplitude of 1.58%.

Recent financial report data shows that the stock achieved operating income of US$18.11 million, net income of US$18.95 million, earnings per share of US$0.43, gross profit--, and a P/E ratio of-5.94 times.

In terms of institutional ratings, among all two institutions participating in the rating, 100% of securities firms gave buy suggestions, and no securities firm gave hold or sell suggestions.

In the biotechnology industry where Tianyan Pharmaceutical shares are located, the overall increase was 0.36%. Among its related stocks, Igm Biosciencesbestcryptogamingplatform, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 (To Pur Com), Humacyte Inc C/Wts 27/08/2026 (To Pur Com) increased significantly, Mustang Bio, Inc., Biodexa Pharmaceuticals Plc and Coeptis Therapeutics Holdings, Inc. are relatively active, with turnover rates of 286.02%, 144.78%, and 38.93%, respectively. Related stocks with larger amplitudes include Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 (To Pur Com), Alpha Tau Medical Ltd C/Wts (To Pur Com), and Oragenics Inc. The amplitudes were 57.14%, 48.75%, and 47.70%, respectively.

Introduction to Tianyan Pharmaceutical Companybestcryptogamingplatform: Tianyan Pharmaceutical Co., Ltd. is a platform-driven clinical biopharmaceutical company engaged in the transformative discovery and development of new antibody-based cancer immunotherapies. It is mainly engaged in the research and development and production of cancer monoclonal antibody drugs. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and multi-species cross-reactivity, which is highlighted in the company's immunotherapy products.

(The above content is Tencent's self-selected shares based on public information and intelligently generated by programs or algorithms. It is only used as a reference for users to watch the market, and is not used as investment advice or trading basis. The stock market is risky, please make decisions carefully.)